Download PDF

1. Company Snapshot

1.a. Company Description

Relay Therapeutics, Inc.operates as a clinical-stage precision medicines company.It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.


The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.It has collaboration and license agreements with D.E.


Shaw Research, LLC to research certain biological targets through the use of D.E.Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc.


for the development and commercialization of RLY-1971.The company was formerly known as Allostery, Inc.and changed its name to Relay Therapeutics, Inc.


in December 2015.Relay Therapeutics, Inc.was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on RLAY

Relay Therapeutics' recent performance was driven by several positive factors. The company's Q2 2025 financial results, announced on August 7, showed a narrower loss of $0.41 per share, beating revenue estimates. Additionally, updated data presented at ASCO demonstrated consistency with prior data, showcasing promising results for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The company's pipeline progress and financial health, with approximately $657 million in cash, cash equivalents, and investments, remain central to its long-term value proposition. A bullish analyst note and participation in investor conferences, including the Morgan Stanley 23rd Annual Global Healthcare Conference, also contributed to positive momentum.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares

Dec -03

Source: fool.com

Card image cap

Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov -22

Source: seekingalpha.com

Card image cap

Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov -06

Source: globenewswire.com

Card image cap

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

Nov -03

Source: globenewswire.com

Card image cap

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

Oct -30

Source: globenewswire.com

Card image cap

Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet

Oct -30

Source: zacks.com

Card image cap

Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy

Oct -28

Source: zacks.com

Card image cap

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Oct -28

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.70%)

6. Segments

Dynamo Platform

Expected Growth: 11.7%

Dynamo Platform's 11.7% growth is driven by increasing adoption in precision medicine, advancements in AI-powered drug discovery, and strategic partnerships. Relay Therapeutics' innovative platform integrates AI, biophysics, and experimental methods, enabling faster and more accurate drug development. Growing demand for targeted therapies and increasing R&D investments in pharma and biotech industries also contribute to the platform's rapid growth.

7. Detailed Products

RLY-1971

RLY-1971 is an oral, small molecule inhibitor of SHP2, a key node in multiple signaling pathways, including RAS and PI3K, that are commonly altered in cancer.

RLY-4008

RLY-4008 is an oral, small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in various cancers.

RLY-3012

RLY-3012 is an oral, small molecule inhibitor of KRASG12C, a specific mutation of the KRAS gene that is commonly found in non-small cell lung cancer.

8. Relay Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Relay Therapeutics, Inc. has a moderate threat of substitutes due to the presence of established pharmaceutical companies and research institutions working on similar therapeutic areas.

Bargaining Power Of Customers

Relay Therapeutics, Inc. has a low bargaining power of customers due to the lack of direct customer interaction, as its primary customers are pharmaceutical companies and research institutions.

Bargaining Power Of Suppliers

Relay Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment, but limited suppliers for specialized services.

Threat Of New Entrants

Relay Therapeutics, Inc. has a high threat of new entrants due to the growing interest in biotechnology and pharmaceutical research, making it easier for new companies to enter the market.

Intensity Of Rivalry

Relay Therapeutics, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among companies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 6.64%
Debt Cost 3.95%
Equity Weight 93.36%
Equity Cost 12.32%
WACC 11.77%
Leverage 7.11%

11. Quality Control: Relay Therapeutics, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Ginkgo Bioworks

A-Score: 4.3/10

Value: 7.8

Growth: 3.3

Quality: 4.3

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Aadi Bioscience

A-Score: 3.9/10

Value: 8.0

Growth: 5.4

Quality: 4.5

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
MeiraGTx

A-Score: 3.8/10

Value: 6.0

Growth: 2.6

Quality: 2.6

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Foghorn Therapeutics

A-Score: 3.8/10

Value: 8.0

Growth: 5.4

Quality: 6.0

Yield: 0.0

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Relay Therapeutics

A-Score: 3.6/10

Value: 6.8

Growth: 6.9

Quality: 3.8

Yield: 0.0

Momentum: 2.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Sutro Biopharma

A-Score: 3.0/10

Value: 9.4

Growth: 2.3

Quality: 4.9

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.68$

Current Price

7.68$

Potential

-0.00%

Expected Cash-Flows